Enhanced muscle function in cause-specific mortality among patients with NAFLD-related sarcopenia.

Liver InternationalVolume 43, Issue 8 p. 1837-1838 LETTER TO THE EDITOR Enhanced muscle function in cause-specific mortality among patients with NAFLD-related sarcopenia Hsien-Hui Chung, Corresponding Author Hsien-Hui Chung [email protected] orcid.org/0000-0001-9284-1365 Department of Pharmacy & Clinical Trial Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan Preventive Medicine Program, Center for General Education, Chung Yuan Christian University, Taoyuan City, Taiwan Department of Pharmacy and Master Program, College of Pharmacy and Health Care, Tajen University, Pingtung County, Taiwan Correspondence Hsien-Hui Chung, Department of Pharmacy & Clinical Trial Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung City 813414, Taiwan. Email: [email protected]Search for more papers by this author Hsien-Hui Chung, Corresponding Author Hsien-Hui Chung [email protected] orcid.org/0000-0001-9284-1365 Department of Pharmacy & Clinical Trial Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan Preventive Medicine Program, Center for General Education, Chung Yuan Christian University, Taoyuan City, Taiwan Department of Pharmacy and Master Program, College of Pharmacy and Health Care, Tajen University, Pingtung County, Taiwan Correspondence Hsien-Hui Chung, Department of Pharmacy & Clinical Trial Pharmacy, Kaohsiung Veterans General Hospital, Kaohsiung City 813414, Taiwan. Email: [email protected]Search for more papers by this author First published: 12 June 2023 https://doi.org/10.1111/liv.15617Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. REFERENCES 1Kim D, Dennis BB, Wijarnpreecha K, Cholankeril G, Ahmed A. Muscle strength in non-alcoholic fatty liver disease and all-cause and cause-specific mortality. Liver Int. 2023; 43(2): 513- 516. 2Sinn DH, Kang D, Kang M, et al. Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: a longitudinal cohort study. Hepatology. 2022; 76(6): 1746- 1754. 3Chakravarthy MV, Siddiqui MS, Forsgren MF, Sanyal AJ. Harnessing muscle-liver crosstalk to treat nonalcoholic steatohepatitis. Front Endocrinol. 2020; 11:592373. 4Silveira EA, da Silva Filho RR, Spexoto MCB, Haghighatdoost F, Sarrafzadegan N, de Oliveira C. The role of sarcopenic obesity in cancer and cardiovascular disease: a synthesis of the evidence on pathophysiological aspects and clinical implications. Int J Mol Sci. 2021; 22(9):4339. 5Alizadeh PH. Exercise therapy for people with sarcopenic obesity: myokines and adipokines as effective actors. Front Endocrinol. 2022; 13:811751. Volume43, Issue8August 2023Pages 1837-1838 ReferencesRelatedInformation